Skip to main content
SpringerLink
Log in

Effects of Inhaled Iloprost on Congenital Heart Disease With Eisenmenger Syndrome

  • Original Article
  • Published:
Pediatric Cardiology Aims and scope Submit manuscript

Abstract

Identification of the pathophysiology associated with Eisenmenger syndrome has led to the evaluation of targeted therapies. Iloprost is one such targeted therapy used for patients with Eisenmenger syndrome. This study aimed to assess the efficacy and safety of iloprost used for patients with Eisenmenger syndrome. In this study, 12 patients with Eisenmenger syndrome (mean age, 33.2 ± 12.1 years; 75% female) started receiving iloprost 10 μg/dose administered six times a day. Of the 12 patients, 9 were classified as New York Heart Association (NYHA) functional class 3, and three were categorized as functional class 4. Changes in 6-min walk distance, NYHA functional class, oxygen saturation at resting, and results after the 6-min walk test were checked, as well as changes in right ventricle diameter and pulmonary arterial pressure shown by echocardiography. The distance during a 6-min walk increased from 255.8 ± 120.4 to 349.4 ± 134.7 m (p = 0.013), and 10 patients improved their NYHA functional class by one grade (p = 0.007). The mean resting oxygen saturation (SpO2) increased from 80.6 ± 14.2 to 84.9 ± 13.0% (p = 0.040), and after the 6-min walk test, it increased from 63.8 ± 22.9 to 68.8 ± 21.5% (p = 0.007). The mean right ventricle diameter during the diastolic phase changed from 53.7 ± 4.8 to 51.4 ± 3.9 mm (p = 0.068), and the mean pulmonary arterial pressure changed from 62.8 ± 13.7 to 58.9 ± 11.7 mmHg (p = 0.059). Neither death nor critical adverse effects occurred for any patients. Mild headache and dyspnea were common reports during the iloprost treatments. No patients stopped the therapy due to these adverse effects. Iloprost is well tolerated and appears to be beneficial in the management of patients with Eisenmenger syndrome.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB, Groves BM, Tapson VF, Bourge RC, Brundage BH et al (1996) A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The primary pulmonary hypertension study group. N Engl J Med 334:296–302

    Article  PubMed  CAS  Google Scholar 

  2. Beghetti M, Galie N (2009) Eisenmenger syndrome: a clinical perspective in a new therapeutic era of pulmonary arterial hypertension. J Am Coll Cardiol 53:733–740

    Article  PubMed  Google Scholar 

  3. Daliento L, Somerville J, Presbitero P, Menti L, Brach-Prever S, Rizzoli G, Stone S (1998) Eisenmenger syndrome: factors relating to deterioration and death. Eur Heart J 19:1845–1855

    Article  PubMed  CAS  Google Scholar 

  4. Eisenmenger V (1897) Die angeborenen Defecte der Kammerscheidewand des Herzens. Z Klin Med 32:1–28

    Google Scholar 

  5. Galie N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D, Fleming T, Parpia T, Burgess G, Branzi A, Grimminger F, Kurzyna M, Simonneau G, Sildenafil Use in Pulmonary Arterial Hypertension (SUPER) Study Group (2005) Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 353:2148–2157

    Article  PubMed  CAS  Google Scholar 

  6. Ghofrani HA, Rose F, Schermuly RT, Olschewski H, Wiedemann R, Kreckel A, Weissmann N, Ghofrani S, Enke B, Seeger W, Gremminger F (2003) Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension. J Am Coll Cardiol. 42:158–164

    Article  PubMed  CAS  Google Scholar 

  7. Goldsmith DR, Wagstaff AJ (2004) Inhaled iloprost: in primary pulmonary hypertension. Drugs 64:763–773

    Article  PubMed  CAS  Google Scholar 

  8. Hoeper M, Leuchte H, Halank M, Wilkens H, Meyer FJ, Seyfarth HJ, Wensel R, Ripken F, Bremer H, Kluge S, Hoeffken G, Behr J (2006) Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension. Eur Resp J 4:691–694

    Article  Google Scholar 

  9. Hopkins WE, Ochoa LL, Richardson GW, Trulock EP (1996) Comparison of the hemodynamics and survival of adults with severe primary pulmonary hypertension or Eisenmenger syndrome. J Heart Lung Transplant 15:100–105

    PubMed  CAS  Google Scholar 

  10. McLoughlin VV, Oudiz RJ, Frost A, Tapson VF, Murali S, Channick RN, Badesch DB, Barst RJ, Hsu HH, Rubin LJ (2006) Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Resp Crit Care Med 174:1257–1263

    Article  Google Scholar 

  11. Mehta PK, Simpson L, Lee EK, Lyle TA, McConnell ME, Book WM (2008) Endothelin receptor antagonists improve exercise tolerance and oxygen saturations in patients with Eisenmenger syndrome and congenital heart defects. Tex Heart Inst J 35:256–261

    PubMed  Google Scholar 

  12. Oh JK, Seward JB, Tajik AJ (2006) The echo manual, 3rd edn. Lippincott Willams & Wilkins, Philadelphia, p 147

    Google Scholar 

  13. Olschewski H, Simonneau G, Galie N, Higenbottam T, Naeije R, Rubin LJ, Nikkho S, Speich R, Hoeper MM, Behr J, Winkler J, Sitbon O, Popov W, Ghofrani HA, Manes A, Kiely DG, Ewert R, Meyer A, Corris PA, Delcroix M, Gomez-Sanchez M, Siedentop H, Seeger W (2002) Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 347:322e9

    Article  Google Scholar 

  14. Olschewski H, Rose F, Schermuly R, Ghofrani HA, Enke B, Olschewski A, Seeger W (2004) Prostacyclin and its analogues in the treatment of pulmonary hypertension. Pharmacol Ther 102:139–153

    Article  PubMed  CAS  Google Scholar 

  15. Oya H, Nagaya N, Uematsu M, Satoh T, Sakamaki F, Kyotani S, Sato N, Nakanishi N, Miyatake K (2002) Poor prognosis and related factors in adults with Eisenmenger syndrome. Am Heart J 143:739–744

    Article  PubMed  Google Scholar 

  16. Pietra GG, Capron F, Stewart S, Leone O, Humber DM, Reid L, Grimminger F, Robbins I, Tuder RM (2004) Pathologic assessment of vasculopathies in pulmonary hypertension. J Am Coll Cardiol 43(1):S25–S32

    Article  Google Scholar 

  17. Reichenberger F, Mainwood A, Coughty N, Fineberg A, Morrell NW, Pepke-Zaba J (2007) Effects of nebulised iloprost on pulmonary function and gas exchange in severe pulmonary hypertension. Respir Med 101:217–222

    Article  PubMed  CAS  Google Scholar 

  18. Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, Pulido T, Frost A, Roux S, Leconte I, Landzberg M, Simonneau G (2002) Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 346:896–903

    Article  PubMed  CAS  Google Scholar 

  19. Schermuly RT, Yilmaz H, Ghofrani HA, Woyda K, Pullamsetti S, Schulz A, Gessler T, Dumitrascu R, Weissmann N, Grimminger F, Seeger W (2005) Inhaled iloprost reversed vascular remodeling in chronic experimental pulmonary hypertension. Am J Respir Crit Care Med 172:336–358

    Article  Google Scholar 

  20. Simonneau G, Barst RJ, Galie N, Naeije R, Rich S, Bourge RC, Keogh A, Oudiz R, Frost A, Blackburn SD, Crow JW, Rubin LJ, Treprostinil Study Group (2002) Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 165:800–804

    PubMed  Google Scholar 

  21. Vongpatanasin W, Brickner ME, Hillis LD, Lange RA (1998) The Eisenmenger syndrome in adults. Ann Intern Med 128:745–755

    PubMed  CAS  Google Scholar 

  22. Wagenvoort CA, Wagenvoort N (1974) Pathology of the Eisenmenger syndrome and primary pulmonary hypertension. Adv Cardiol 11:123–130

    PubMed  CAS  Google Scholar 

  23. Wilkens H, Guth A, Koenig J, Forestier N, Cremers B, Hennen B, Böhm M, Sybrecht G (2001) Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension. Circulation 104:1218–1222

    Article  PubMed  CAS  Google Scholar 

  24. Wood P (1958) The Eisenmenger syndrome or pulmonary hypertension with reversed central shunt. Br Med J 2:701–709

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Pediatric Cardiology, Cardiovascular Center, Gil Hospital, Gachon University, 1198 Kuwol-dong, Namdong-gu, Incheon, 405-760, Korea

    Song I Yang & Deok Young Choi

  2. Division of Cardiology, Cardiovascular Center, Gil Hospital, Gachon University, Incheon, Korea

    Wook Jin Chung

  3. Division of Pulmonology, Cardiovascular Center, Gil Hospital, Gachon University, Incheon, Korea

    Sung Hwan Jung

Authors
  1. Song I Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Wook Jin Chung
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sung Hwan Jung
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Deok Young Choi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Deok Young Choi.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yang, S.I., Chung, W.J., Jung, S.H. et al. Effects of Inhaled Iloprost on Congenital Heart Disease With Eisenmenger Syndrome. Pediatr Cardiol 33, 744–748 (2012). https://doi.org/10.1007/s00246-012-0204-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00246-012-0204-0

Keywords

Search

Navigation